Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode

Pediatric Infectious Disease Journal

Volumn 26, Issue 9, 2007, Pages 794-798

  Santolaya, María E ^a,b,i   Alvarez, Ana M ^b,c   Avilés, Carmen L ^b,d   Becker, Ana ^b,e   Mosso, Claudio ^a,b   O'Ryan, Miguel ^f   Payá, Ernesto ^b,g   Salgado, Carmen ^b,g   Silva, Pamela ^b,d   Topelberg, Santiago ^b,h   Tordecilla, Juan ^b,h   Varas, Mónica ^b,c   Villarroel, Milena ^a,b   Viviani, Tamara ^b,e   Zubieta, Marcela ^b,g  

^a HOSPITAL LUIS CALVO MACKENNA   (Chile)

^b Subcommittee of Infectious Diseases   (Chile)

^c Hospital San Juan de Dios

^d HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^e HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^f UNIVERSITY OF CHILE   (Chile)

^g Pediatra Reumatólogo Unidad Inmuno Reumatología Hospital Dr Exequiel González Cortés   (Chile)

^h HOSPITAL ROBERTO DEL RÍO   (Chile)

ⁱ NONE   (Chile)

Author keywords

Children with cancer; Febrile neutropenia; Mortality

Indexed keywords

AMIKACIN; C REACTIVE PROTEIN; CEFTAZIDIME; OXACILLIN; VANCOMYCIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; INFANT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MORTALITY; MULTICENTER STUDY; NEUTROPHIL COUNT; PRIORITY JOURNAL; RELAPSE; SEPSIS; SURVIVAL RATE; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CHILE; FEMALE; FEVER; HUMANS; INFANT; MALE; MEDICAL RECORDS; NEOPLASMS; NEUTROPENIA; RECURRENCE; RISK FACTORS; SEPSIS; SURVIVORS;

EID: 34548268684     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e318124aa44     Document Type: Article

References (23)

1. Gonzalez-Barca E, Fernandez-Sevilla A, Carrratala J. Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis. 1999;18:539-544.
2. Wilbur D, Rentschler R, Couperus J. Identifying neutropenic febrile cancer patients at risk for early death. Infect Med. 2000;17:347-354.
3. Kuderer N, Dale D, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258-2266.
4. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. J Clin Oncol. 2001;19:3415-3421.
5. Basu S, Fernández I, Fisher S, et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23:7958-7966.
6. Santolaya ME, Alvarez AM, Aviles CL, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever and neutropenia. Clin Infect Dis. 2002;35:678-683.
7. Santolaya ME, Alvarez AM, Avilés CL, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever and neutropenia at low risk for invasive bacterial infection. J Clin Oncol. 2004;22:3784-3789.
8. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328:1323-1332.
9. Campbell M, Salgado C, Quintana J, et al. Mejoría en el pronóstico de la leucemia linfoblástica aguda en niños de un país en desarrollo: resultados del protocolo nacional chileno PINDA 87. Rev Chil Pediatr. 1999;70:405-414.
10. Santolaya ME, Alvarez AM, Avilés CL, et al. Advancing in the development of a risk prediction model for sepsis in children with cancer, fever and neutropenia. In: Program and Abstract of the 45th Interscience Conference on Antimicrobial Agent and Chemotherapy. Washington, DC: American Society for Microbiology; 2005:254:. Abstract G-1358.
11. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
12. Santolaya ME, Rabagliatti R, Bidart T, et al. Consenso nacional: manejo racional del paciente con neutropenia y fiebre. Rev Chilena Infectol. 2005;22:S79-S113.
13. Payá E, Alvarez AM, Aviles CL, et al. Agentes causantes de infecciones del torrente circulatorio en niños con cáncer, en cinco hospitales de Santiago (1994-1998). Rev Med Chile. 2001;129:1297-1304.
14. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
15. Freifeld A, Marchigiani D, Walsh T, et al. A double blind, comparison of empiric oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999;341:305-311.
16. Kern WV, Cometta A, de Bock R, et al. Oral versus intravenous empiric antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med. 1999;341:312-318.
17. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051.
18. Aquino V, Tkaezewski Y, Buchanan G. Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis. 1997;25:74-78.
19. Klaassen RJ, Goodman TR, Pham B, et al. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18:1012-1019.
20. Paganini H, Gomez S, Ruvinsky S, et al. Outpatient, sequencial, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease. Cancer. 2003;97:1775-1780.
21. Park J, Coughlin J, Hawkins D, et al. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients. Med Pediatr Oncol. 2003;40:93-98.
22. Kern W, Heiss M, Steinbach G. Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empiric monotherapy versus combination therapy. Clin Infect Dis. 2001;32:832-835.
23. Rackoff W, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol. 1996;14:919-924.